/WGS
WGS Stock - GeneDx Holdings Corp.
Healthcare|Medical - Healthcare Information ServicesNASDAQ
$140.44+3.02%
+$4.12 (+3.02%) • Dec 19
69
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.80
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).89
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.38
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+19.3%upside
Target: $167.54
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for WGS
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$139.04 – $141.84
TARGET (TP)$167.50
STOP LOSS$129.20
RISK/REWARD1:2.4
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta2.04
52W High$170.87
52W Low$55.17
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $305.45M | $202.57M | $234.69M | $212.19M | $179.32M |
| Gross Profit | $194.40M | $90.01M | $-26,750,000 | $-16,602,000 | $4.03M |
| Gross Margin | 63.6% | 44.4% | -11.4% | -7.8% | 2.2% |
| Operating Income | $-23,213,000 | $-180,596,000 | $-667,652,000 | $-446,149,000 | $-241,994,000 |
| Net Income | $-52,286,000 | $-175,767,000 | $-548,980,000 | $-245,390,000 | $-241,340,000 |
| Net Margin | -17.1% | -86.8% | -233.9% | -115.6% | -134.6% |
| EPS | $-1.94 | $-7.23 | $-53.63 | $-74.93 | $-33.16 |
Company Overview
GeneDx Holdings Corp. is a patient centered health intelligence company. It engages in transforming healthcare by applying AI and machine learning to multidimensional, longitudinal clinical and genomic data to build dynamic models of human health and defining optimal, individualized health trajectories. The firm, through its Centrellis health intelligence platform, generates a more complete understanding of disease and wellness and provides science-driven solutions to the most pressing medical needs. The company was founded by Eric Schadt in October 2015 and is headquartered in Stamford, CT.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
4
67%
Hold / Neutral
2
33%
Sell / Underperform
0%
Analyst Consensus🟡 Mixed
4 Bullish2 Neutral/Bearish
Price Targets
$76
Average Target
↓ 46.0% Downside
Now
$21
Low
$76
Average
$155
High
Based on 7 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| October 20th 2025 | Canaccord Genuity | Initiation | Buy | $155 |
| July 9th 2025 | Piper Sandler | Initiation | Overweight | $110 |
| May 15th 2025 | Guggenheim | Initiation | Buy | $88 |
| May 9th 2025 | Jefferies | Upgrade | Buy | $80 |
| August 28th 2024 | Wells Fargo | Initiation | Equal Weight | $34 |
| July 10th 2024 | Craig Hallum | Initiation | Buy | $43 |
| June 3rd 2024 | Jefferies | Resumed | Hold | $21 |
Earnings History & Surprises
WGSBeat Rate
65%
Last 17 quarters
Avg Surprise
+135.1%
EPS vs Estimate
Beats / Misses
11/5
1 met exactly
Latest EPS
$0.49
Q4 2025
EPS Surprise History
Q1 24
+1.7%
$-0.59vs$-0.60
Q2 24
+51.5%
$-0.33vs$-0.68
Q3 24
+57.7%
$-0.11vs$-0.26
Q4 24
+121.1%
$0.04vs$-0.19
Q1 25
+1650.0%
$0.70vs$0.04
Q2 25
+154.5%
$0.28vs$0.11
Q3 25
+400.0%
$0.50vs$0.10
Q4 25
+75.0%
$0.49vs$0.28
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | Apr 28, 2026 | — | — | — | — |
Q1 2026 | Feb 17, 2026 | $0.11 | — | — | — |
Q4 2025 | Oct 28, 2025 | $0.28 | $0.49 | +75.0% | ✓ BEAT |
Q3 2025 | Jul 29, 2025 | $0.10 | $0.50 | +400.0% | ✓ BEAT |
Q2 2025 | Apr 30, 2025 | $0.11 | $0.28 | +154.5% | ✓ BEAT |
Q1 2025 | Feb 18, 2025 | $0.04 | $0.70 | +1650.0% | ✓ BEAT |
Q4 2024 | Oct 29, 2024 | $-0.19 | $0.04 | +121.1% | ✓ BEAT |
Q3 2024 | Jul 30, 2024 | $-0.26 | $-0.11 | +57.7% | ✓ BEAT |
Q2 2024 | Apr 29, 2024 | $-0.68 | $-0.33 | +51.5% | ✓ BEAT |
Q1 2024 | Feb 20, 2024 | $-0.60 | $-0.59 | +1.7% | ✓ BEAT |
Q4 2023 | Oct 30, 2023 | $-1.18 | $-0.82 | +30.5% | ✓ BEAT |
Q3 2023 | Aug 8, 2023 | $-1.47 | $-1.65 | -12.2% | ✗ MISS |
Q2 2023 | May 9, 2023 | $-1.65 | $-2.82 | -70.9% | ✗ MISS |
Q1 2023 | Mar 14, 2023 | $-0.16 | $-0.25 | -56.3% | ✗ MISS |
Q4 2022 | Nov 14, 2022 | $-0.21 | $-0.20 | +4.8% | ✓ BEAT |
Q3 2022 | Aug 15, 2022 | $-0.21 | $-0.25 | -19.0% | ✗ MISS |
Q2 2022 | May 12, 2022 | $-0.31 | $-0.31 | 0.0% | = MET |
Q1 2022 | Mar 14, 2022 | $-0.26 | $-0.17 | +34.6% | ✓ BEAT |
Q4 2021 | Nov 15, 2021 | $-0.19 | $-0.43 | -126.3% | ✗ MISS |
Q3 2021 | Jul 21, 2021 | — | $-25.86 | — | — |
Latest News
Wells Fargo Maintains Equal-Weight on GeneDx Holdings, Raises Price Target to $155
➖ NeutralBenzinga•Dec 15, 2025, 06:18 PM
GeneDx's GUARDIAN Study Honored By JAMA For Demonstrating Genomic Newborn Screening Can Detect Serious Childhood Conditions Missed By Traditional Methods
📈 PositiveBenzinga•Dec 15, 2025, 01:55 PM
BTIG Maintains Buy on GeneDx Holdings, Raises Price Target to $200
📈 PositiveBenzinga•Dec 12, 2025, 11:09 AM
GeneDx To Present Four Research Sessions At The 2025 National Society Of Genetic Counselors Annual Meeting, Showcasing Advances Powered By Its Genedx Infinity Platform
📈 PositiveBenzinga•Nov 6, 2025, 01:13 PM
Wells Fargo Maintains Equal-Weight on GeneDx Holdings, Raises Price Target to $140
📈 PositiveBenzinga•Nov 4, 2025, 04:05 PM
Canaccord Genuity Maintains Buy on GeneDx Holdings, Raises Price Target to $160
📈 PositiveBenzinga•Oct 29, 2025, 08:54 PM•Also:
Guggenheim Maintains Buy on GeneDx Holdings, Raises Price Target to $170
📈 PositiveBenzinga•Oct 29, 2025, 12:43 PM
BTIG Maintains Buy on GeneDx Holdings, Raises Price Target to $165
📈 PositiveBenzinga•Oct 29, 2025, 09:47 AM
CORRECTION: GeneDx Hldgs Q3 Adj. EPS $0.49 Beats $0.42 Estimate, Sales $116.743M Beat $104.670M Estimate
📈 PositiveBenzinga•Oct 28, 2025, 10:44 AM
GeneDx Holdings Corp. Non-GAAP EPS of $0.49 beats by $0.07, revenue of $116.74M beats by $12.07M
📈 PositiveSeeking Alpha•Oct 28, 2025, 10:33 AM
GeneDx Holdings Raises FY2025 Sales Guidance from $400.000M-$415.000M to $425.000M-$428.000M vs $411.682M Est
📈 PositiveBenzinga•Oct 28, 2025, 10:32 AM
BTIG Maintains Buy on GeneDx Holdings, Raises Price Target to $140
📈 PositiveBenzinga•Oct 22, 2025, 12:10 PM
Granted FDA Grants Breakthrough Device Designation To GeneDx's ExomeDx And GenomeDx Tests
📈 PositiveBenzinga•Oct 20, 2025, 12:10 PM
Canaccord Genuity Initiates Coverage On GeneDx Holdings with Buy Rating, Announces Price Target of $155
📈 PositiveBenzinga•Oct 20, 2025, 10:48 AM•Also:
GeneDx Launches First U.S. National Genomic Newborn Screening Initiative Funded By $14.4M NIH Award
📈 PositiveBenzinga•Oct 1, 2025, 08:04 PM
Piper Sandler Maintains Overweight on GeneDx Holdings, Raises Price Target to $140
📈 PositiveBenzinga•Sep 11, 2025, 02:07 PM
GeneDx a new overweight at Piper Sandler on rare diseases testing market
📈 PositiveSeeking Alpha•Jul 9, 2025, 02:17 PM
GeneDx soars as pediatrics group recommends genome testing for developmental delay
📈 PositiveSeeking Alpha•Jun 23, 2025, 08:31 PM
GeneDx Holdings stock trades higher as upgraded at Jefferies
📈 PositiveSeeking Alpha•May 9, 2025, 04:21 PM
GeneDx plunges despite Q1 beat and guidance raise
📉 NegativeSeeking Alpha•Apr 30, 2025, 02:47 PM
Frequently Asked Questions about WGS
What is WGS's current stock price?
GeneDx Holdings Corp. (WGS) is currently trading at $140.44 per share. The stock has moved +3.02% today.
What is the analyst price target for WGS?
The average analyst price target for WGS is $167.50, based on 1 analyst.
What sector is GeneDx Holdings Corp. in?
GeneDx Holdings Corp. operates in the Healthcare sector, specifically within the Medical - Healthcare Information Services industry. The company is traded on the NASDAQ exchange.
What is WGS's market cap?
GeneDx Holdings Corp. has a market capitalization of $4.06 billion, making it a mid-cap company.
Does WGS pay dividends?
No, GeneDx Holdings Corp. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorCRNX
Crinetics Pharmaceuticals, Inc.
$48.01
Mkt Cap: $4.6B
HNGE
Hinge Health, Inc.
$47.25
Mkt Cap: $3.7B
IMVT
Immunovant, Inc.
$26.68
Mkt Cap: $4.7B
KYMR
Kymera Therapeutics, Inc.
$83.99
Mkt Cap: $6.0B
NAMS
NewAmsterdam Pharma Company N.V.
$35.11
Mkt Cap: $4.0B
OPCH
Option Care Health, Inc.
$32.51
Mkt Cap: $5.4B
OSCR
Oscar Health, Inc.
$14.90
Mkt Cap: $3.8B
PRVA
Privia Health Group, Inc.
$23.64
Mkt Cap: $2.9B
TMDX
TransMedics Group, Inc.
$127.67
Mkt Cap: $4.4B
VKTX
Viking Therapeutics, Inc.
$35.19
Mkt Cap: $4.0B
Explore stocks similar to WGS for comparison